Nasus Pharma Doses First Patient in Phase 1 Trial for Intranasal Ondansetron

  • Nasus Pharma dosed the first patient in its Phase 1 pharmacokinetic trial for NS003, an intranasal powder formulation of ondansetron, targeting chemotherapy-induced and post-operative nausea.
  • Pre-clinical studies showed NS003's pharmacokinetic profile was comparable to intravenous ondansetron, with a favorable safety profile at four times the test dose.
  • The company aims to announce topline pharmacokinetic data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4 2026.
  • Ondansetron, a widely prescribed anti-emetic, had over 12 million prescriptions in 2023, with Zofran® peak sales exceeding $1.5 billion.

Nasus Pharma's Phase 1 trial for NS003 marks a strategic push into the anti-emetic market, where ondansetron remains a cornerstone therapy. The company's intranasal powder technology aims to address unmet needs in chemotherapy-induced and post-operative nausea, potentially reducing clinic visits and improving patient convenience. With over $1.5 billion in peak sales for Zofran®, the market opportunity is substantial, but success hinges on demonstrating superior efficacy and safety in human trials.

Clinical Execution
Whether NS003 can replicate its pre-clinical pharmacokinetic success in human trials, potentially offering a faster, needle-free alternative to intravenous ondansetron.
Market Differentiation
How Nasus Pharma positions NS003 against established oral and intravenous ondansetron formulations, leveraging its proprietary powder-based intranasal technology.
Regulatory Pathway
The pace at which Nasus Pharma advances NS003 through clinical trials, aiming for a pivotal study initiation by year-end 2026.